Vanta Bioscience Limited (VANTABIO.BO)
INR 21.96
(4.97%)
INR 21.96
(4.97%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -30.64 Million | -65.13 Million | 28.75 Million | 47.29 Million | -17.92 Million | -55.06 Million |
| Net Income | -23.15 Million | -64.8 Million | 882.07 Thousand | 4.49 Million | 10.04 Million | 6.96 Million |
| Depreciation & Amortization | 44.96 Million | 26.7 Million | 13.16 Million | 12.51 Million | 11.88 Million | 7.1 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 13.07 Million | 10.79 Million | 13.87 Million | 30.13 Million | -40.88 Million | -70.9 Million |
| Other non-cash items | 9.13 Million | -37.82 Million | 837.62 Thousand | 149.4 Thousand | 1.01 Million | 77.23 Million |
| Investing Cash Flow | -33.13 Million | -59.08 Million | -171.8 Million | -221.94 Million | -73.51 Million | -54.95 Million |
| Investments in PPE | -34.04 Million | -286.89 Million | -171.8 Million | -221.94 Million | -73.51 Million | -24.75 Million |
| Acquisitions | 915 Thousand | 227.8 Million | - | - | - | -30.19 Million |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 915 Thousand | - | - | -10.00 | - | - |
| Financing Cash Flow | 64.42 Million | 122.94 Million | 118.79 Million | 199.2 Million | 41.23 Million | 116.31 Million |
| Debt repayment | -37.92 Million | -122.94 Million | -88.96 Million | -186 Million | -41.23 Million | -116.31 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 26.5 Million | - | 29.82 Million | 13.2 Million | - | - |
| Other Financing Activities | -57.48 Million | 245.89 Million | 177.93 Million | 372 Million | 82.46 Million | 232.63 Million |
| Accounts receivables | -11.82 Million | -8.24 Million | 8.8 Million | -6.23 Million | 1.72 Million | -13.04 Million |
| Accounts payables | 30.71 Million | 12.85 Million | -3 Million | 5.54 Million | 40.33 Million | 13.99 Million |
| Inventory | -3.63 Million | 780.13 Thousand | 25.28 Million | 42.43 Million | -47.63 Million | -62.19 Million |
| Other working capital | -2.19 Million | 5.4 Million | -17.21 Million | -11.6 Million | -35.3 Million | -9.65 Million |
| Cash at beginning of period | 966.47 Thousand | 2.24 Million | 26.5 Million | 1.95 Million | 32.66 Million | 873.23 Thousand |
| Cash at end of period | 1.6 Million | 966.47 Thousand | 2.24 Million | 26.5 Million | 1.95 Million | 32.66 Million |
| Capital Expenditure | -34.04 Million | -286.89 Million | -171.8 Million | -221.94 Million | -73.51 Million | -24.75 Million |
| Effect of forex changes on cash | - | -1.00 | - | 1.00 | 19.5 Million | 25.49 Million |
| Net cash flow / Change in cash | 639.53 Thousand | -1.27 Million | -24.26 Million | 24.55 Million | -30.71 Million | 31.78 Million |
| Free Cash Flow | -64.69 Million | -352.02 Million | -143.05 Million | -174.65 Million | -91.44 Million | -79.82 Million |
| Breakdown | 2023 Q4 | 2023 FY | 2023 Q2 | 2022 Q4 | 2022 FY | 2022 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -17.79 Million | -23.15 Million | -5.36 Million | -39.2 Million | -64.8 Million | -25.6 Million |
| Depreciation & Amortization | 29.52 Million | 44.96 Million | 15.44 Million | 13.59 Million | 26.7 Million | 13.1 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 14.34 Million | 13.07 Million | -1.27 Million | -31.45 Million | 10.79 Million | 42.24 Million |
| Other non-cash items | 25.86 Million | 9.13 Million | 13.99 Million | 43.46 Million | -37.82 Million | -33.26 Million |
| Investing Cash Flow | -16.69 Million | -33.13 Million | -16.43 Million | -23.13 Million | -59.08 Million | -35.95 Million |
| Investments in PPE | -17.61 Million | -34.04 Million | -16.43 Million | -43.5 Million | -286.89 Million | -243.38 Million |
| Acquisitions | 915 Thousand | 915 Thousand | - | 20.37 Million | 227.8 Million | 207.43 Million |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 38.4 Million | 64.42 Million | 26.01 Million | 100.39 Million | 122.94 Million | 22.55 Million |
| Debt repayment | -38.4 Million | -37.92 Million | -481 Thousand | -100.39 Million | -122.94 Million | -22.55 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 26.5 Million | 26.5 Million | - | - | - |
| Other Financing Activities | - | - | - | -1000.00 | 245.89 Million | 45.1 Million |
| Accounts receivables | -10.59 Million | -11.82 Million | -1.22 Million | -7.12 Million | -8.24 Million | -1.12 Million |
| Accounts payables | - | 30.71 Million | - | -30.7 Million | 12.85 Million | 43.55 Million |
| Inventory | -4.12 Million | -3.63 Million | 491 Thousand | 1.43 Million | 780.13 Thousand | -650 Thousand |
| Other working capital | -1.66 Million | -2.19 Million | -536 Thousand | 4.95 Million | 5.4 Million | 457 Thousand |
| Cash at beginning of period | 1.36 Million | 966.47 Thousand | 966.47 Thousand | 902 Thousand | 2.24 Million | 2.24 Million |
| Cash at end of period | 1.6 Million | 1.6 Million | 1.36 Million | 966.47 Thousand | 966.47 Thousand | 902 Thousand |
| Capital Expenditure | -17.61 Million | -34.04 Million | -16.43 Million | -43.5 Million | -286.89 Million | -243.38 Million |
| Effect of forex changes on cash | - | - | -361.47 Thousand | -690.00 | -1.00 | 690.00 |
| Net cash flow / Change in cash | 240 Thousand | 639.53 Thousand | 399.53 Thousand | 64.47 Thousand | -1.27 Million | -1.34 Million |
| Free Cash Flow | -39.43 Million | -64.69 Million | -25.25 Million | -120.7 Million | -352.02 Million | -231.32 Million |
ALMOU
DEEPAKCHEM
AKRIT
ZWELCAST
ICDSLTD
MOGAN